Note: Descriptions are shown in the official language in which they were submitted.
CA 02820562 2013-07-10
ACTIVATING ADIPOSE-DERIVED STEM CELLS FOR TRANSPLANTATION
TECHNICAL FIELD
[0001] The present invention relates generally to methods of preparing
stem cell
preparations and to kits for preparing stem cell preparations used to treat
bone, ligament, tendon
or cartilage injury.
BACKGROUND
[0002] Musculoskeletal injuries and degenerative bone and joint diseases
can be
disabling. Those affected can suffer from reduced mobility and range of motion
in addition to
experiencing discomfort and pain_ The joint of an animal refers generally to
the location within
the body where two bones are attached in close proximity. Joints are arranged
to allow
movement and provide structural support. In general, the two bones at the
joint are separated by
layers of articular cartilage on the opposing surfaces of the two joining
bones with a synovial
cavity containing synovial fluid between the layers of articular cartilage to
provide lubrication
for movement at the joint. The synovial cavity is further enclosed by a
synovial lining
surrounding the joint. Additional connective tissues including ligaments hold
the bones at the
joint together by attachment to the opposing bones. Similarly, tendons further
connect muscle to
one of the bones to allow for mechanical movement. Many injuries, conditions
and diseases
involve the joint and surrounding tissue.
[0003) Following injury or tissue damage, tissues may regenerate new
functional cells
either by division of existing functional cells or by differentiation of stern
cells present in the
tissue to form new functional cells. However, unwanted scar tissue may also
form as part of the
normal healing process which might impair regeneration and elasticity.
Recently, stem cell
transplants have been proposed as a treatment option for degeneration, damage
or injury of the
joint and other musculoskeletal tissues to promote tissue regeneration and
restore function and
performance while reducing pain and discomfort to the animal. These approaches
are aimed at
tipping the balance away from non-functional repair mechanisms and toward
regeneration of
functional cells. But, what are needed in the art are improved methods and
compositions for
isolating and activating particular stem cell fractions for the treatment of
these diseases and
1
CA 02820562 2013-07-10
=
conditions.
SUMMARY
[0004] In accordance with purposes described herein a method is provided
for preparing
a stem cell preparation used in treating a bone, ligament, tendon or cartilage
injury in an animal
such as a mammal. The method may be broadly described as including a step of
collecting
adipose tissue from a source animal. That adipose tissue includes fat,
connective tissue and stem
cells. In addition the method includes contacting the adipose tissue with an
enzyme preparation
that digests the fat and connective tissue while preserving the stem cells of
the adipose tissue and
then collecting those stem cells. The method may be characterized by the
enzyme preparation
including collagenase from Clostridium histolyticum and protease from
Bascillus
thermoproteolyticus.
[0005] In one embodiment the method further includes providing between 55
¨ 65 wt%
collagenase from Clostridium histolyticum to 45 ¨ 35 wt% protease from
Bascillus
thermoproteolyticus of the enzymes in the enzyme preparation. In addition the
enzyme
preparation includes a biologically inert protein stabilizer selected from a
group of stabilizers
consisting of a neutral salt, a sugar, sodium chloride, calcium chloride,
glucose, fructose,
sucrose, trehalose, mannose, dextrose and mixtures thereof.
[0006] That method may be further described as including collecting blood
from the
source animal and preparing a platelet rich plasma. The platelet rich plasma
is prepared by
separating the blood into a plasma layer and a red blood cell layer,
collecting the plasma layer,
separating the plasma layer into a platelet poor plasma layer and a platelet
rich plasma layer and
collecting the platelet rich plasma. In some embodiments the method further
includes activating
the platelet rich plasma by mixing the platelet rich plasma with an activating
solution including,
for example, a calcium chloride solution.
[0007] In accordance with an additional aspect, a method is provided for
treating a
mammal for a bone, ligament, tendon or cartilage injury. That method includes
administering to
a treatment animal a composition including a therapeutically effective amount
of the stem cell
preparation prepared by the current method. In one application the source
animal and the
CA 02820562 2013-07-10
treatment animal are the same animal. In some embodiments the animal is a
mammal.
[0008] In accordance with yet another aspect, a kit is provided for
preparing a stem cell
preparation from adipose tissue. The kit may be broadly described as
comprising a first sterile
vessel of an enzyme preparation including collagenase from Clostridium
histolyticum and
protease from Bascillus thermoproteolyticus. In some embodiments the enzyme
preparation
includes between 55-65% collagenase from Clostridium histolyticum and 45-35%
protease from
Bascillus thermoproteolyticus. In some embodiments the kit includes a second
sterile vessel of a
plasma activation preparation_ In some embodiments the plasma activation
preparation
comprises a calcium chloride solution.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The accompanying drawings incorporated herein and forming a part of
the
specification, illustrate several aspects of the present invention and
together with the description
serve to explain certain principles of the invention. In the drawings:
[0010] Figures la and lb illustrates canine stem cell differentiation;
[0011] Figures 2a-2f illustrate possible injection sites for stem cell
preparation; and
[0012] Figure 3 illustrates a kit for preparing the stern cell
preparation.
[0013] Reference will now be made in detail to the present preferred
embodiment of the
invention, examples of which are illustrated in the accompanying drawings.
DETAILED DESCRIPTION
[0014] Where the definition of terms departs from the commonly used
meaning of the
term, applicant intends to utilize the definitions provided below, unless
specifically indicated.
[0015i Stem cell - A stem cell must meet the following criteria: (1)
ability of a clonal
stem cell population to self-renew; (2) ability of a clonal stem cell
population to generate a new,
terminally differentiated cell type in vitro; and (3) ability of a clonal stem
cell population to
replace an absent terminally differentiated cell population when transplanted
into an animal
3
CA 02820562 2013-07-10
depleted of its own natural cells. (self-renew ¨ numerous cell division in
undiff state; potency ¨
diff into diverse cell types).
[0016] "Adipose stem or stromal cells" refers to multipotent strornal
cells or stem cells
that originate from adipose tissue and are capable of self-renewal. By
"adipose" is meant any fat
tissue. The adipose tissue may be brown or white adipose tissue, derived from
subcutaneous,
omental/visceral, mammary, gonadal, or other adipose tissue site. In one
embodiment, the
adipose is subcutaneous white adipose tissue. Such cells may comprise a
primary cell culture or
an immortalized cell line. The adipose tissue may be from any organism having
fat tissue.
[0017] Regenerative medicine provides a treatment option for wound healing
as well as
repair or restoration of damaged, injured, degenerative or diseased tissue.
Regenerative
medicine basically harnesses the ability of regenerative cells (e.g., stem
cells and/or progenitor
cells), to renew themselves and develop into more mature specialized cells,
such as by
administering these cells to sites of tissue damage, injury, disease or
degeneration to promote
healing or repair (i.e., encouraging regeneration of functional cells rather
than non-functional
repair mechanisms, such as scar formation).
[0018] Stem cells are present in the body of an animal -throughout
development. Stem
cells may be found in embryos during early stages of development as well as in
fetal and adult
organs and tissues. Embryonic stem cells (or "ESCs") are generally
undifferentiated and have
the ability to become many different cell and tissue types within the body.
Thus, it is believed
that these cells may have tremendous potential for regenerative applications.
However, because
ESCs are necessarily derived from another individual (i.e., an embryo), there
is a risk that a
recipient's immune system will reject the new biological material, and
immunosuppressive drugs
may have limited effectiveness with these procedures and can create problems
on their own.
Moreover, transplanted ESCs have been shown to form tumors (e.g., teratomas),
and the use of at
least human ESCs may be obstructed by ethical concerns. Even in non-human
animals, ESCs
may be difficult to obtain and grow in large numbers.
[0019] Adult stem cells (or "ASCs") represent an alternative to the use of
ESCs. ASCs
reside quietly in many adult tissues, presumably waiting to respond to normal
senescence,
trauma or destructive disease processes so that they can heal the injured or
diseased tissue and/or
4
CA 02820562 2013-07-10
maintain normal tissue. Each individual carries a pool of ASCs that may have
the potential to
differentiate into many types of cells and tissues. These cells, unlike ESCs,
may be used
autologously to treat a diseased or injured tissue. ASC populations have been
shown, for
example, to be present in bone marrow, skin, fat, muscle, liver and brain.
Thus, ASCs may have
the potential for use in regenerative medicine. ASCs have been shown to have
multiple
regenerative actions including the ability to differentiate into mature
functional cells, to produce
trophic factors for tissue support and to modulate immune responses and
inflammation.
[0020] However, the frequency and number of ASCs in many adult tissues is
very low.
These numbers of ASCs further tend to decline with age, contributing to
reduced ability of
tissues to repair and replenish themselves. In addition, extraction of ASCs
from some tissues
may require involved cell culturing steps, and it may take a considerable
amount of time to
isolate or concentrate the ASCs. Bone marrow transplantation provides a
classic example where
hematopoietic stem and progenitor cells are harvested from a donor and used to
replenish the
blood forming capacity of a recipient. But, the utility of bone marrow-derived
stem cells for
tissue engineering has been limited, due in part to low stem cell numbers and
their tendency to
differentiate. Induced pluripotent stem cells (iPS cells) from differentiated
or partially
differentiated adult cells have also been proposed recently, but these
procedures generally
require cellular alterations and/or genetic modification.
[0021] Accordingly, successful application of ASCs for regenerative
medicine purposes
may be greatly improved if the number and purity of progenitor or stem cells
harvested from a
tissue could be increased and if the length of time required to prepare,
isolate, concentrate, etc.,
the ASC population is shortened. These regenerative techniques using ASCs
might be further
improved by preparing new cellular fractions containing ASCs that may have
more favorable
characteristics and/or by developing new methods for beneficially activating
or triggering
differentiation of ASCs before their administration to a recipient animal.
[0022] During development, early embryonic cells are considered to be
largely totipotent
and remain pluripotent through much of differentiation. There are three main
germ layers or
lineages formed during animal development. The ectoderm generally gives rise
to skin and
neural tissue, the endoderm generally forms the respiratory and digestive
systems, and the
CA 02820562 2013-07-10
mesoderm generally gives rise to cartilage, bone, fat, muscle, tendon and
blood.
[0023] Mesenchymal stem cells (or "MSCs"), are a collection of cells
mostly derived
from the mesoderm that are present in diverse fetal and adult tissue types and
may form part of
the tissue stroma. These MSCs are considered multipotent and may become cells
of many
supportive tissues including bone (osteoblasts), cartilage (chondrocytes) and
fat (adipocytes).
MSCs are a distinct group of stem cells that are separate from liematopoietic
stem cells. MSCs
have been shown to have the ability to migrate to sites of injury and
encourage tissue repair
through proliferation and extracellular matrix production. Because of their
ability to form
structural tissue types, MSCs are proposed for use in regenerative medicine to
promote healing,
repair, restoration, etc., of damaged, injured, diseased, degenerative, etc.,
tissues.
[0024] Although present in many diverse tissue types, MSCs from bone
marrow and
adipose tissue may be the most promising for regenerative applications.
Mesenchymal stem cells
occur naturally in many tissues, but generally only in small amounts. As a
result, it is difficult to
isolate MSCs from tissue, and harvesting these cells from bone marrow is
associated with a lot of
pain to the donor. Recently, adipose tissue has been shown to be a rich source
of MSCs. Unlike
bone marrow and other tissues, adipose tissue is comparably easy to harvest in
relatively large
amounts (e.g., up to 1000 times the quantity of marrow) due to its abundance
(especially in obese
animals) and its ability to replenish itself. Thus, delays caused by culturing
steps for expansion
and to meet therapeutic thresholds are eliminated. Adipose-derived MSCs are
also present in
relatively much higher concentrations (e.g., 1000 times more stem cells than
in marrow), and
extraction of adipose tissue is generally less invasive due to its
accessibility, less painful and
safer compared to extraction of MSCs from other tissues. Furthermore, adipose-
derived stem
cells (AD-SCs) or adipose-derived mesenchymal stem cells (AD-MSCs) have been
shown to
possess the ability to generate multiple tissues, including bone, fat,
cartilage, and muscle despite
being in an "inactive" state when extracted. As with other ASCs, use of AD-
MSCs does not
require a second donor animal. Thus, adipose tissue is proposed as an optimal
source for ASCs
for use in regenerative medicine.
[0025] The method of preparing a stem cell preparation for treating a
bone, ligament,
tendon or cartilage injury in an animal such as a mammal comprises a number of
steps. For
6
CA 02820562 2013-07-10
purposes of the method an animal includes particularly a mammal such as a dog,
cat or horse.
The method may be broadly described as comprising the steps of: (a) collecting
adipose tissue
from a source animal where that adipose tissue includes fat, connective tissue
and stem cells, (b)
contacting the adipose tissue with an enzyme preparation that digests the fat
and connective
tissue while preserving the stem cells of the adipose tissue, and (c)
collecting the stem cells. The
method is particularly characterized by the enzyme preparation which includes
collagenase from
Clostridium histolyticum and protease from Bascillus thermoproteolyticus.
In some
embodiments the method includes providing between 55-65 wt% collagenase from
Clostridium
histolyticum and 45-35 wt% protease from Bascillus thermoproteolyticus of the
enzymes in the
enzyme preparation. In some embodiments the method includes providing about 60
wt%
collagenase from Clostridium histolyticum and about 40 wt% protease from
Bascillus
thermoproteolyticus of the enzymes in the enzyme preparation. Still further
the method includes
providing a biologically inert protein stabilizer in the enzyme preparation.
The protein stabilizer
may comprise up to 70 or 80 wt% of the final enzyme preparation with the
enzyme mixture of
35-45 wt% protease and 55-65 wt% comprising the other 20 to 30 wt% of the
final enzyme
preparation. That protein stabilizer may be selected from a group of
stabilizers consisting of a
neutral salt, a sugar, sodium chloride, calcium chloride, glucose, fructose,
sucrose, trehalose,
mannose, dextrose and mixtures thereof. The enzyme preparation may also
include other
additives such as glycylglycine and calcium chloride in small amounts.
[0026]
The preparation of the enzyme preparation is further described in Example I
presented below.
The method may be further described as including the collecting of blood from
the source animal
and preparing a platelet rich plasma from that blood. The platelet rich plasma
is prepared in a
two-step separation process. First the blood is separated into a plasma layer
and a blood cell
layer. This is followed by the collecting of the plasma layer. The collected
plasma layer is then
separated into a platelet poor plasma layer and a platelet rich plasma. This
is followed by the
collecting of the platelet rich plasma. hi some embodiments the method then
includes activating
the platelet rich plasma by mixing the platelet rich plasma with an activating
solution. Such an
activating solution may include but is not limited to a calcium chloride
solution having a
concentration of between about 1.8 % and about 3.8%. In some embodiments the
method then
7
CA 02820562 2013-07-10
includes mixing the platelet rich plasma with the collected stem cells in
order to activate the stem
cells and form the stem cell preparation.
[0027] Still further a method of treating an animal for bone, ligament,
tendon or cartilage
injury is provided. That method may be broadly described as comprising the
administering to a
treatment animal a composition including a therapeutically effective amount of
the stem cell
preparation disclosed in this document. In some particularly useful
embodiments the source
animal and the treatment animal are the same animal. In some embodiments the
animal is a
mammal. In some embodiments the animal is a dog. In some embodiments the
animal is a cat.
In some embodiments the animal is a horse.
[0028] In accordance with yet another aspect a kit is provided for
preparing a stem cell
preparation from adipose tissue of an animal. The kit may be broadly described
as comprising a
first sterile vessel of an enzyme preparation including collagenase from
Clostridium histolyticum
and protease from Bascillus thermoproteolyticus. In some particularly useful
embodiments the
enzyme preparation includes between 55-65 wt% collagenase from Clostridium
histolyticum and
45-35 wt% protease from Bascillus thermoproteolyticus of the enzymes in the
final preparation.
In some useful embodiments the kit includes a second sterile vessel of a
plasma activation
preparation. In some embodiments that plasma activation preparation includes a
calcium
chloride solution.
[0029] A more detailed description of the preparation method, treatment
method and kit
follows.
Preparation Method
[0030] According to one broad aspect of the present invention, a new
method, protocol or
procedure is provided for extracting adipose-derived stem cells for transfer
into an animal for
treatment of joint or musculoskeletal tissue injury, disease, damage or
degeneration. The present
methods may provide for a particular sequence of purification steps, including
various washes,
centrifugation and digestion steps, to isolate, purify, produce, concentrate,
etc., a unique stromal
vascular fraction (SW) containing AD-MSCs for therapeutic use. In addition to
the AD-MSCs,
the SVF produced by these procedures may also contain additional factors,
peptides and other
8
CA 02820562 2013-07-10
multipotent cells. According to some embodiments, the SVF containing AD-MSCs
may be
applied or administered autologously to the same animal. Alternatively, the
SVF or AD-MSC
cells may also be applied allogeneically or syngeneically. One advantage of
administering cells
or fractions autologously is safety in that the potential for immune responses
and disease
transmission may be reduced, minimized or eliminated. Also, because the
ingredients may be
obtained from the same animal being treated, it should be considered
acceptable for use with
performance animals, such as race horses. Another advantage of methods of the
present
invention is that all of the steps may be performed entirely in-house as part
of a single,
continuous process or procedure wider the care or supervision of a doctor or
veterinarian.
Alternatively, however, the tissues and samples may be sent to an outside
facility for extraction
and processing,
[0031] AD-MSCs are believed to reside in a perivascular location in
adipose tissue and
may include and/or coexist with pericytes and endothelial cells. AD-MSCs may
exert the
regenerative potential through a number of activities. AD-MSCs have been shown
to be
immunomodulatory and anti-inflammatory, such as by immunosuppression,
inhibition of T-cell
proliferation, induction of regulatory lymphocytes and through apoptosis of
CD8+ lymphocytes.
Some of these effects may be mediated through the release or excretion of
chemokines,
cytokines and extra,cellular matrix proteins. MSCs may also enhance
proliferation, migration
and differentiation of endogenous stem cells in most tissues of the body, such
as through cell-cell
contact and mitochondrial exchange. Perhaps primarily, AD-MSCs may exert their
regenerative
and repair potential through their own differentiation into functional cells,
such as by forming
cartilage, chondrocytes, osteoblasts and/or improved tendon fiber
reorganization, Other
components of the SVF apart from the MSCs, which may include various factors
and other
multipotent cell types, may further enhance these features and provide
additional benefits,
including anti-inflammatory effects, biofactors and bioactive peptides and
factors that contribute
to reformation and architectural organization of tissues.
=
[0032] The International Society for Cellular Therapy has defined at least
one set of
minimal criteria for MSCs within a SVF from bone marrow or other tissues: The
cells should
adhere to plastic when cultured under standard conditions in a tissue culture
flask, As
exemplified in Figures 1 a and lb, the cells should be able to differentiate
into osteoblasts (which
9
CA 02820562 2013-07-10
may be confirmed by Alzarin Red staining), chondroblasts (which may be
confirmed by Alcian
blue staining) and adipocytes (which may be confirmed by Oil Red 0 staining)
when cultured in
differentiating conditions. When measured by flow cytometry, 95% or more of
the cells should
express: CD105, CD73, and CD90 and lack expression of: CD45, CD34, CD14, CDI
lb, CD79a
or CD19; and 2% or less of the cells should have HLA class IL With flow
cytometry, surface
markers may be labeled with fluorescent markers and read with the use of a
laser and electric
field.
[0033] Figures la and lb shows that AD-MSCs prepared according to methods
described
herein are capable of differentiating into multiple tissue types. For example,
Figures 1 a and lb
demonstrates osteoid-tissue formation from cultured AD-MSCs prepared according
to present
methods with Alzarin red S staining with the pink color indicating bone
mineral calcification.
Osteocyte induction medium changed the cells from a fibroblastic appearance to
a more cuboidal
appearance, and were surrounded with an abundant matrix and formed mineralized
nodules.
Figures 1 a and lb also demonstrate adipose tissue formation from the AD-MSCs
with Oil Red 0
staining. Cultures were treated with adipogenic induction media, resulting in
abundant quantities
of vacuoles observed in the cells after time. The Oil Red 0 (red) staining for
fat revealed that
these vacuoles contained neutral lipids. DAPI (blue) staining is used to
indicate the cell nucleus.
Figures la and lb further demonstrate cartilage tissue formation from the AD-
MSCs with alcian
blue staining. Cultures were treated with chondroge,riie induction medium and
were intensely
stained with alcian blue (blue), indicating a high content of
mucopolysaccharides, which are
associated with chondrocyte differentiation.
[0034] The SVF extracted, isolated, purified, concentrated, etc., by
methods of the
present invention may contain bone marrow stromal cells, follicular dendritic
cells, and
mesenchymal cells and/or one or more of the following as determined by FACS
analysis:
hematopoietic CD45 cells (e.g., about 9%), monocyte porogenitor CD14 cells
(e.g., about 11 %),
early committed progenitor and mature granulocyte/monocyte CD13 cells (e.g.,
about 6%),
hematopoietic CD90 stern cells (e.g., about 29%), early lymphohemopoietic stem
and progenitor
CD34/CD133 cells (e.g., about 7%), cells having endothelial-associated markers
including
CD31, CD105 and CD146, endothelial CD45/CD146 UEA-1 cells and CD271 cells
(e.g., about
0.6%).
CA 02820562 2013-07-10
[0035] In addition, the SVF extracted, isolated, purified, concentrated,
etc,, by methods
of the present invention may further contain many beneficial proteins that
encourage bone
formation, liver cell regeneration, nervous system regeneration, wound
healing, vascular
rebuilding, skin and damaged cell repair and/or re-growth. The SVF may contain
one or more of
the following: thymosine beta-4 (controls T cell maturation and helps damaged
cells repair
themselves), osteoclast-stimulating factor 1 (bone formation), caveolin-1
(liver regeneration and
lipogenesis), ephrin-A I (involved in the developing nervous system and
erythropoietin),
connective tissue growth factor (wound healing skin fibroblast stimulator, and
endothelial
angiogenesis), and transforming growth factor beta-2. The SVF may also contain
various
proteins present in the extracellular matrix of adipose tissue, such as
laminin.
[0036] According to embodiments of the present invention, adipose tissue
is extracted or
removed from an animal to obtain stem cells. Through a series of steps, a
stomal vascular
fraction (SVF) containing AD-MSCs may be isolated, purified, concentrated,
etc., from the
extracted adipose tissue. All volumes and other amounts described herein with
regard to
embodiments of the present invention may be increased or decreased
proportionally to alter
yields, such as depending on the type and size of the animal to be treated, In
general, sterile
and/or aseptic procedures should always be used, including wearing gloves,
masks and haimets
and disinfecting work surfaces.
[0037] According to some embodiments, before beginning the tissue
extraction, various
solutions may be prepared in anticipation of the procedure. A solution
containing an enzyme
preparation for digestion of tissues during the procedure may be prepared,
such as by adding
water or a solution to solubilize a powder or dry formulation of the enzyme(s)
(perhaps with
other ingredients) or to dilute a concentrated solution containing the
enzyme(s). For example, a
volume of sterile phosphate buffered solution (PBS) (e.g., about 1.0 ml) may
be added to the
enzyme(s) solution, The enzyme solution in combination with the one or more
volumes of water
and/or solution should be mixed well. The enzyme used in the preparation will
generally include
one or more enzymes for digesting the adipose tissue, such as proteases and
the like (see below).
Sterile procedures should always be used. Alternatively, the enzyme solution
may have been
previously prepared and stored, such as in a refrigerator or freezer.
11
CA 02820562 2013-07-10
[0038] An
antibiotic solution may also be prepared if not previously prepared and stored
for use during the extraction procedure. For example, the antibiotic solution
may include
gentarnicin/Gentocin (Schering). For example, a solution (e.g., about 0.5 ml)
of the antibiotic
(e.g., about 40 mg/m1) may be added to a solution (or a solution may be added
to the antibiotic
solution), such as by using a syringe and needle, and mixed well. The solution
combined or
added to the antibiotic solution may be sterile phosphate buffered solution
(PBS) (e.g,, about
19.5 m1). In addition, a volume of the antibiotic solution may be further
diluted by addition of a
volume of the antibiotic solution (e.g., about 5.0 ml) to another sterile
phosphate buffered
solution (PBS) (e.g., about 95 ml), such as by using a syringe and needle, and
mixed well.
Sterile procedures should always be used.
[0039]
According to embodiments of the present invention, a platelet-rich plasma
(PR?)
may be used to "activate" or trigger differentiation of the SVF and/or other
beneficial changes,
such as proliferation and release or excretion of factors and extracellular
matrix, to AD-MS Cs
when added to the SVF or (see below). The PRP may be prepared either in
advance or in
parallel with the adipose tissue extraction procedure. The PRP is prepared
from the blood of an
animal and may contain growth factors in addition to other beneficial
biomolecules. Preferably,
the PRP may be prepared from the same animal from which the adipose tissue is
extracted, such
that the PRP-treated SVF may be autologously administered or applied to the
same animal.
[0040]
According to these embodiments, a blood sample is first taken from the animal
and placed into one or more tubes, such as blood collection tubes (e.g.. ACD-A
venous blood
collection tubes). For example, the venous blood (e.g., about 15 ml or about
50 to 100 cc)
collected from a donor or source animal may be placed into three ACID-A tubes
(e.g., about 5 ml
apiece), such as up to a mark or line on the tubes. This should generally be
done under strict
aseptic conditions. Once collected, the tubes may be inverted or mixed, such
as about 8 times.
The collection tube(s) containing the blood samples may be centrifuged at
about 1000 g (i.e.,
about 2500 rpm) for about 4 minutes. After centrifugation, the top plasma
layer is removed from
each tube(s) and placed into a new tube (e.g., 15 ml tube), which may be done
with the same
syringe or pipette if transferred from more than one tube. Care should be
taken to avoid drawing
up the blood cell layer containing erythrocytes and a thin layer of white
cells (buffy coat). To
achieve this it may be advisable to avoid taking the last portion (e.g. about
5nun) of plasma
12
CA 02820562 2013-07-10
above the blood cell layer. Once the plasma layer is transferred to a new
tube, it should be
centrifuged again at about 1000g (2500rpm) for about eight minutes, At the end
of this
centrifugation step, there should be a platelet-containing pellet at the
bottom of the tube. The top
platelet-poor plasma should be removed and discarded. However, not all of the
plasma above
the pellet should be removed. Instead, a portion of the plasma (e.g., about 3
ml of plasma)
should be left in the tube. This remaining portion of plasma should then be
used to resuspend the
platelet-rich pellet, which may be done using the same syringe or pipette used
to remove and
discard the plasma. This resuspension constitutes the platelet-rich plasma
(PRP).
[0041] According to embodiments of the present invention, the PRP produced
by this
procedure may include one or more of the following components: platelet-
derived growth factor
(PDGF), TB-4 (may control T cell maturation and make damaged cells repair
themselves),
osteoclast-stimulating factor 1 (bone formation), caveolin-1 (liver
regeneration and lipogenesis),
Ephrin-Al (involved in the developing nervous system and erythropoietin),
connective tissue
growth factor (CTGF; wound healing, skin fibroblast stimulator, endothelial
angiogenesis), TGF-
a and TGF-0 (transforming growth factors alpha & beta), epidermal growth
factor (EGF),
fibroblast growth factor (FGF), insulin growth factor (IGF), platelet derived
epidermal growth
factor (PDEGF), platelet derived angiogenesis factor (PDAF), interleulcin-8
(IL-8), tumor
necrosis factor alpha (TNF-a), granulocyte macrophage colony stimulating
factor (GM-CSF),
keratinocyte growth factor (KGF), histamines, serotonin, ADP, thromboxane A2,
and other
vasoactive and chemotactie agents. There may also be high concentrations of
leukocytes
(neutrophils, eosinophils; microbicidal), wound macrophages and phagocytes
(biological
debridement), and platelets and native fibrinogen. Platelets may play a role
in wound healing
and provide hemostasis and release mediators to help modulate inflammatory
responses and
many of the above factors may be located in the alpha granuales of platelets.
Albeit more
concentrated, the PRP may contain factors including those listed above in
roughly the same
ratios or proportions as they exist in the body.
[0042] According to some embodiments, the PRP may itself be "activated"
for later use
by adding a volume of an activator solution such as a calcium chloride (CaC12)
solution to the
PRP. For example, about 0.5 ml of CaC1 solution may be added to the PRP, such
as by using a
syringe or pipette. This activator solution initiates the clotting cascade
prior to the platelets
13
CA 02820562 2013-07-10
being injected or placed in vivo allowing for growth factor release from the
platelets. This
expulsion of growth factors along with other bioactive molecules allows the
growth factors to
come into direct contact with additional signaling from the body of an animal
receiving
treatment. Activation results in rapid growth factor release with perhaps 90%
of the
prefabricated factors being released in ten minutes. Since many growth factors
have short half-
lives, this quick release provides significant benefit so long as the
activated platelet rich plasma
is used within about 240 minutes.
(0043] After mixing, the activated PRP should form a gel, such as in about
15-60
minutes This reaction may be accelerated by placing in a 37 C bath (shaking
should preferably
be avoided). Once this gel has formed, the tube or vial containing the PRP may
be left at room
temperature for a period of time, such as about 1-2 hours. During this time,
the PRP will at least
partially dissolve. However, the gelled PRP may not completely dissolve, and
the rate of
dissolution may depend on blood chemistry and overall health of the animal. In
any case, there
should generally be enough dissolved PRP for later use even if it is only
partially dissolved. The
activated PRP solution may be left aside in anticipation of its use during the
SVF procedure.
Again, the dissolution of this gel may be accelerated or sped up by placing in
a 37 C bath
(shaking is optional). If at the end of this period, the gel is attached to
the side of the tube, the
tube may be vigorously jolted or tapped and allowed to dissolve for an
additional short period of
time or released by use of a spinal needle or sterile transfer pipette.
(0044) According to embodiments of the present invention, a method of
processing
adipose tissue surgically collected from an animal, such as a mammal, to
produce, isolate, purify,
fractionate, extract, concentrate, etc., a stromal vascular fraction (SVF)
including adipose-
derived stem cells, such as AD-MSCs, is provided. In a first step, an amount
or volume of
adipose tissue is removed from a donor or source animal, which may be the same
as the recipient
animal to be treated. The amount or volume of adipose tissue may depend on the
type and size
of animal and the amount, volume or number of SVF or AD-SCs desired for
treatment, For
example, the amount or volume of adipose tissue may depend on the body mass
index and age of
the donor, the time available for collection, the availability of accessible
adipose tissue harvest
sites, and the clinical purpose for which the tissue is being collected
including the number of
locations or joints to treat. The adipose tissue may be collected, obtained,
extracted or removed
14
CA 02820562 2013-07-10
according to any method known in the art. For example, adipose tissue may be
removed from a
patient by liposuction (syringe or power assisted) or by lipectomy, such as
suction-assisted
lipoplasty, ultrasound-assisted lipoplasty, and excisional lipectomy or
combinations thereof,
Adipose tissue is present in various accessible locations throughout the body
of an animal and
may be obtained, for example, from the thorax, inguinal or rump area of the
animal. The animal
may also receive an anesthetic for comfort.
10045] According to embodiments wherein the adipose tissue is excised by
lipectomy,
the adipose tissue may be removed or excised and placed in a vessel or
container (e.g., 70 ml
container). According to some embodiments, the amount of adipose tissue
excised and placed
into a specimen container or jar may be from about 5 to about 20 grams of
adipose tissue. The
size of the specimen container should be large enough to allow the addition of
solutions, such as
at least about twice the volume as that of the tissue. The amount of stem
cells obtained by the
procedure is roughly proportional to the amount of tissue excised or removed.
[0046] In the case of adipose tissue removed by lipectomy, once the amount
or volume of
excised adipose tissue is placed into the specimen container or jar, the
tissue should be finely cut
or minced using scissors or other sharp utensil such that the tissue is
divided into individual
pieces of adipose tissue that are very small (e.g., about 2-4 mm apiece in
size). Other tissues,
such as muscle, should also be removed and discarded as much as possible. The
fat tissue may
now resemble a slurry. The finely cut adipose tissue may now be poured or
transferred into a
new tube, such as a SO ml tube. Preferably, there should generally be about 5-
20 ml of tissue. If
there is extra tissue, amounts above 20 nil may be discarded.
[0047] To digest and break up the tissue and release the individual cells,
an enzymatic
step may be employed. The enzyme preparation used is available from MediVet
America LLC
under the trademark Medistem. The enzyme preparation includes:
Ingredient 1: 60%:40% mixture of naturally derived, purified class I: class II
collagenase
from Clostridium histolyticum, with a total collagen degradation activity
(CDA, as
defined in Transplantation Proceedings 40:339, 2008) per bottle 0.08 grams of
powder
solute of 100,000 20,000 CDA units,
Ingredient 2: Naturally derived, purified neutral protease from Bascillus
CA 02820562 2013-07-10
therrnoproteo/yticus with a total neural protease activity (NPA as defined in
Transplantation Proceeding 42:2052, 2010) of 100,000 20,000 NPA Units, and
Ingredient 3: A biologically inert compound for its protein stabilization
affect.
[0048]
Such a biologically inert compound may include but is not limited to protein
stabilizers consisting of a neutral salt, a sugar, sodium chloride, calcium
chloride, glucose,
fructose, sucrose, trehalose, mannose, dextrose and mixtures thereof. In one
embodiment of the
method, about 0.4 ml of the enzyme preparation is added to the adipose tissue
using a sterile
syringe and needle. Following this, an amount of an antimicrobial wash
solution, such as
phosphate buffered saline (PBS) + 0.5 ml of 40 mg/ml Gentacin antimicrobial
(e.g., about 2 ml),
may be added, such as by syringe and needle, to raise the volume, An
additional volume of
solution, such as PBS, may be added, such as by syringe and needle, to raise
the total volume to
a desired amount, such as about 40 ml,
[0049]
Following these steps, the contents may be mixed well by inverting the tube Or
container and placing in a 37 C water bath, and the tube may also be shaken
or agitated, Lower
temperatures may also be used less preferably. The digestion reaction may then
be allowed to
incubate for a period of time, such as about 45 minutes. To keep the contents
from settling to the
bottom, the tube may be optionally removed every 10-15 minutes for agitating,
mixing or
inverting and placement back into the bath and a thin layer of white cells
(buffy coat), To
achieve this, it may be advisable to avoid taking the last portion (e.g.,
about 5 mm) of plasma
above the blood cell layer. Once the plasma layer is transferred to a new
tube, it should be
centrifuged again at about 1000 g (2500 rpm) for about 8 minutes. (As an
optional step, the
solutions described above may be prepared during this longer centrifugation
step in anticipation
of the adipose extraction procedure to conserve time.)
[0050]
According to embodiments of the present invention, after the enzymatic
digestion reaction, a cell extraction medium may be added. According to some
embodiments,
the cell extraction medium may include an emulsifier or surfactant and may be
lecithin-based
(phosphatidyl choline), soy lecithin-based or glyceryl ester-based. For
example, a volume of
about 4 ml of a lecithin or soy lecithin-based solution may be added, such as
by using a needle
and syringe. Such a lecithin-based solution may be thick or viscous. Thus, it
may be necessary
16
CA 02820562 2013-07-10
to draw up the cell extraction solution slowly while moving the tip of the
needle. Once the cell
extraction medium is added to the digested adipose tissue, it may be incubated
for a period of
time (e.g., about 15 minutes) and may be mixed or inverted occasionally (e.g.,
at about 7
minutes). This incubation step may also be warmed, such as in a 37 C bath.
[0051] Following this cell extraction step, the processed adipose tissue
may be
centrifuged, such as at about 800g (about 2300 rpm), for a period of time,
such as about 10
minutes, As a result of this step, three layers may be formed in the tube: a
top yellow/clear layer;
a white fibrous middle layer; and a red bottom layer having a cell pellet at
the bottom of the tube
(this pellet is the SVF containing the stem cells including AD-MSCs). Next,
the bottom red
layer containing the cell pellet may be removed and placed into a new
container or tube. The red
layer may be drawn up and transferred using a pipette, cannula and/or syringe,
such as by
inserting a cannula or pipette slowly down the side of the tube. All of the
cell pellet and most of
the red layer may be removed and transferred to a new container. Care should
be taken to avoid
taking the white fibrous layer because it may clog a filter later in the
procedure. Thus, it may be
advisable to stop drawing up the red layer when the white fibrous layer is
near the bottom of the
tube. The cannula or pipette tip may also be used to gently scrape pelleted
cells off the surface
of the tube. The red layer plus cells drawn up into the pipette, cannula
and/or syringe may then
be transferred or expelled into a new tube, such as a 50 ml tube. The rest of
what remains of the
adipose tissue preparation including the white fibrous layer and top
yellow/clear layer may be
discarded.
[0052] The stem cell-containing preparation produced by the steps above
may be filtered
to remove larger particles and debris. The pore size of the filter may be, for
example, about 100
gra. This filtering step may also be done under vacuum to draw the fluid
preparation by suction
and/or gravity into another container or tube. The stem cell preparation may
be transferred or
poured onto a filter attached to another tube. However, it is preferred that
contact with the
environment is minimized, such as by directly attaching the sample tube
containing the stem cell
preparation to a new tube. For example, a Steriflip filter unit (Millipore)
may be attached to
the tube containing the stem cell preparation. The Sterifiip filter unit may
include a tube
attached to a filter with a vacuum hookup or spigot for attaching a vacuum
line or pump, such as
a hand or motorized pump, to create suction into the new tube. A Steriflip
filter unit may be
17
CA 02820562 2013-07-10
attached to the top of the sample tube containing the stem cell preparation
and then inverted or
flipped one time such that the new receiving tube is underneath and the stem
cell preparation
flows down onto the filter surface by gravity. The stem cell preparation may
then be filtered by
gravity and/or under vacuum pressure. The filtered stem cell preparation in
the new container or
tube (such as a 50 ml tube) may be capped, and the used filter and the old
sample tube may be
discarded.
[0053]
Once the stem cell preparation is filtered into the new tube, it may be
centrifuged
at about 800 g (about 2300 rpm) for a period of time, such as about 10
minutes. As a result, a
cell pellet of SVF containing the stem cells is again formed. The supernatant
(the red liquid)
may be removed using a pipette or syringe without disturbing the cell pellet.
Attempts should be
made to remove the brown fatty liquid on top of the supernatant. Approximately
1-3 ml of the
supernatant above the pellet may be left behind, which may then be used to
resuspend the pellet
using the same pipette or syringe. To this resuspension, a wash volume of PBS
+ Gentacin
antimicrobial, such as about 20 ml, may be added to the tube and mixed well.
The centrifugation
step above is then repeated, and the supernatant (except for about 1-3 ml) is
mostly removed and
discarded. To this resuspension, a wash volume of PBS, such as about 12 ml,
may be added to
the tube and mixed well. It is important that the cell pellet be fully broken
up in the resuspension
for the next filtering step. However, some fibrous material may be present
which is normal and
will be removed in the next step.
[0054]
This filtered and washed stem cell preparation may then be filtered again to
remove additional debris and particles. The pore size of this second filter
may be smaller, such
as about 60 fun. This filtering step may also be done under vacuum to draw the
fluid preparation
by suction and/or gravity into another container or tube. The stem cell
preparation may be
transferred or poured onto a filter attached to another tube. However, it is
preferred that contact
with the environment is minimized, such as by directly attaching the sample
tube containing the
stem cell preparation to a new tube. For example, a Steriflipe filter unit
(Millipore) may be
attached to the tube containing the stem cell preparation. The Steriflip
filter unit may include a
tube attached to a filter with a vacuum hookup or spigot for attaching a
vacuum line or pump to
create suction into the new tube. A Steriflipt filter unit may be attached to
the top of the tube
containing the stem cell preparation and then inverted or flipped one time
such that the new
18
CA 02820562 2013-07-10
receiving tube is underneath and the stem cell preparation flows down onto the
filter surface by
gravity. The stem cell preparation may then be filtered by gravity and/or
under vacuum pressure.
The filtered stem cell preparation in the new container or tube (such as a 50
ml tube) may be
capped, and the used filter and the previous sample tube may be discarded.
[0055] The filtered stem cell preparation may then be transferred to a new
tube, such as a
15 ml tube, such as by using a pipette or syringe, and this sample may then be
centrifuged again
at about 800 g (about 2300 rpm) for a period of time, such as about 10
minutes. Similarly to
above, most of the supernatant may be removed and discarded. However, a small
volume (e.g.,
about 0.5 ml) may be left behind with the pellet. Again, the cell pellet
represents the SVF and
may contain red and white cells in addition to stem cells.
[0056] According to embodiments of the present invention, a volume of PR?,
which may
be prepared as described above, may be added to, combined with, etc., the
remaining volume
containing the stem cell pellet to activate (e.g., trigger differentiation or
cause other beneficial or
favorable changes to) the SVF and/or AD-SCs due to the presence of active
proteins and factors
in the PRP. For example, a volume of the dissolved portion of the partially
dissolved PRP
described above may be added to the remaining volume containing the stem cell
pellet, such as
until the total volume reaches about 1-2 ml. The PRY preparation may have been
left to dissolve
while the above adipose extraction procedure was carried out. However, the
volume of PRP
added may depend on the number of locations or joints to be treated. When
treating a. joint, it
should be kept in mind that (depending on which joint and the size of the
animal) typically no
greater than about 0.5 ml of the combined SVF/PRP preparation should be added
to the joint of
an animal. In general, the volume of PRP added may be about the same as the
volume
containing the stem cell pellet. Once the PRP is added, the SVF or stem cell
pellet may then be
resuspended, such as by using the pipette or syringe used to transfer the
PR.?. This resuspension
may be mixed until it forms a single cell suspension.
[0057] According to some embodiments, the SVF and/or AD-SCs prepared as
described
herein, such as the combined SVF/PRP preparation described above, may be
subjected to light
stimulation or photobiostimulation to activate (e.g., trigger differentiation
or cause other
beneficial or favorable changes to) the SVF and/or AD-SCs. Light sensitive
molecules and
19
CA 02820562 2013-07-10
substances have been shown to be present in cells. Indeed, stem cells have
been shown to be
responsive or activated by light. Several molecules in fibroblasts have been
shown to be
photoacceptors, and fibroblasts have been shown to absorb light at various
frequencies (e.g., 420,
445, 470, 560, 630, 690 and 730 run). Five light frequency ranges (two in the
green part of the
spectrum, one in the yellow part of the spectrum and two in the red part of
the spectrum) were
found to stimulate AD-MSCs (e.g., cause proliferation), whereas frequencies in
the blue part of
the spectrum were found to inhibit these cells.
[0058] Using combinations of these wavelengths in the green, yellow and
red parts of the
light spectrum has stronger effects than individual wavelengths alone, and use
of
photostimulation in addition to PRP treatment further increases the
stimulatory effect on AD-
MSCs than either alone. The combination of exposure to PRP in addition to
photostimulation
greatly increases the amount of growth and/or proliferation of AD-SCs. In
experiments, cultures
of SVF and/or AD-SCs from a canine source either receiving PRP and
photostimulation were
compared after 8 days to those receiving no activation. The colony sizes for
the activated cell
cultures were significantly increased (e.g., about 19% in this example) over
controls. The effects
of both PRP and light stimulation were greater over time than either PRP or
light activation
alone. In these experiments, AD-SCs were cultured in DMEM medium with serum
with or
without PRP and light stimulated (where applicable) by exposure to the laser
for about 30
minutes. In addition, activation caused by photostimulation was dependent on
the wavelength of
light used as discussed above with some combinations of light wavelengths
resulting in even
greater stimulation.
[0059] According to some embodiments, photostimulation at wavelength(s)
within these
ranges of the visual light spectrum may be used to stimulate the SW' and/or AD-
MSCs
preparation with or without further stimulation or activation by exposure of
the SVF and/or AD-
MSCs to PRP. Although the PRP is preferably added to the SVF prior to
photostimulation, it
may optionally be added after the light treatment. To photostimulate the SVF
and/or AD-MSCs
preparation (with or without the PRP having been added) may be transferred to
a new tube or
container, such as a cryotube (e.g., 2.5 ml cryotube). According to
embodiments wherein the
PRP is used, additional volume of PRP may be added to raise the volume if
needed for effective
light treatment. The tube containing the SVF and/or AD-MSCs may then be placed
into the
CA 02820562 2013-07-10
photobiostimulation unit, (which is basically an enclosed or mostly enclosed
space for holding a
sample and one or more light source(s), such as LED or laser lights, for
stimulation of the sample
in the path of the light). Once the tube and cells are placed in the unit the
light source(s) in the
unit may be turned on for a period of time, such as for about 20 minutes, to
emit one or more of
the five stimulatory wavelengths (two in the green part of the spectrum, one
in the yellow part of
the spectrum and two in the red part of the spectrum). See, e.g.,
PCT/CN2010/072041 filed
April 22, 2010, the entire contents and disclosures of which are incorporated
herein by reference.
After this step, the photostimulation step may be considered complete.
[0060] Following these procedures, the number of cells may be counted or
quantified
according to any method known in the art, such as by using a FACS,
haemocytometer,
microscope or suitable coulter counter, Cell types may also be identified and
counted by type,
and viable cells may be quantitated according to known methods. Based on these
measurements,
the number of cells may be calculated. These cell numbers may be used to
determine the amount
or volume of cells to use for treatment.
[0061] Following these procedures, the number of cells may be counted or
quantified
according to any method known in the art, such as by using a FACS,
haemocytometer,
microscope or suitable coulter counter. Cell types may also be identified and
counted by type,
and viable cells may be quantitated according to known methods, Based on these
measurements,
the number of cells may be calculated. These cell numbers may be used to
determine the amount
or volume of cells to use for treatment.
Treatment Method
[0062] According to another broad aspect of the present approach, a method
of treating
an animal, such as a mammal, is provided by administering a composition
including a
therapeutically effective amount of the stern cell preparation having the SVF
and/or AD-MSCs
prepared according to the procedures described herein, which may also have
been stimulated or
activated by PRP exposure. The activated stem cell preparation may then be
applied or
administered to an animal, which may be the same animal from which the PRP
and/or SVF was
derived (i.e., autologously applied in that the donor or source animal is the
same as the recipient
or treated animal). Alternatively, the activated SVF or stem cell preparation
may be applied or
21
CA 02820562 2013-07-10
administered to an animal, which is different than the animal from which one
or both of the pRp
and/or SVF was derived. In these less preferred cases, however, the PR? and/or
SVF
preparations should be derived from a closely related animal or species, such
that the PRP and/or
SVF are applied allogeneically or syngeneically to avoid or minimize adverse
reactions.
[0063] According to embodiments of the present invention, an animal having
or
experiencing an injury or damaged, degenerative or diseased tissue may be
treated or
administered a composition comprising the stem cell preparation produced
according to the
methods described herein. Typically, the composition comprising the stem cell
preparation may
be applied or injected to the particular location(s) or site(s) of the injury
or damaged,
degenerative or diseased tissue. However, intravenous (i.v.) and/or
intraperitoneal (i.p.)
administration of these compositions is also envisioned especially for more
systemic conditions
or diseases or those involving multiple locations (e.g,, multiple joints) in
the body. Many
injuries, conditions and diseases involve the joint and surrounding tissue
including arthritis and
osteoarthritis, arthropathy, ligament and tendon injuries, and bone fractures.
Thus, embodiments
of the present invention provide for local administration of compositions
produced by present
methods to the joint and/or surrounding tissue. However, administration of the
present
compositions may in some cases be counter-indicated for safety where there is
active or recent
remission of cancer or latent or overt infection.
[0064] According to some embodiments, an animal to be treated may be taken
off all
non-essentially medications for about 7-14 days including immune-suppressive
drugs and
steroids. Prior to and after treatment, the animal may be given NSAIDs. In
those embodiments
where the composition will be injected into the one or more of the location(s)
or site(s), the stem
cell preparation, in the form of a suspension may be drawn up into at least
one syringe, such as a
1.0 ml or a 2.0 ml syringe, with the amount depending on the number of
locations to be treated.
In the case where injection is to be made into a joint, a maximum amount
injected into the joint
in the case of an animal about the size of a large dog or smaller may
generally be about 0.5 ml,
whereas the maximum amount injected may instead be about 0.2 ml for smaller
animals (e.g., in
the case of an animal about the size of a small dog). In the case of an animal
corresponding to
the size of a large dog or smaller, the maximum amount may alternatively be an
amount derived
from about 10 ml of adipose tissue or less. However, the amount or volume to
be injected may
22
CA 02820562 2013-07-10
vary and depend on the size and type of the animal as well as the particular
tissue or joint to be
mated, Indeed, the maximum amount injected into the joint of a large animal or
tissue other
than a joint may be greater than 0.5 ml. Although not usually preferred,
compositions
comprising SVF and/or AD-MSCs prepared according to methods described herein
may be
administered or injected in combination with one or more physiologically or
pharmaceutically
suitable carriers or solutions.
[0065] Following treatment with the SVF and/or AD-MSCs, the needle and
treatment site
may be flushed with an antibiotic, such as Gentocin /Gentamicin (e.g., about 2
mg/kg body
weight divided by the number of locations or joints to be treated). However,
total
Gentocine/Gentamicin injected into the joint should generally not exceed about
25 mg or about
3 mg/kg body weight. In addition, the animal may continue to be treated with
general antibiotics
for a period of time thereafter, such as for about 5-7 days.
Injection examples
[0066] According to some embodiments, the composition comprising the stem
cell
preparation including SVF and/or AD-MSCs prepared according to methods
described herein
may be administered or injected into a joint of an animal (i.e., by intn-
articular injection)
according to any method known in the art. Such injection into a joint may be
performed
similarly to arthrocentesis or arthrodesis procedures for the respective
joint. Figures 2a-2f
provide some examples for injection into various joints of a canine. For
example, Figure 2a
shows possible injection into the "wrist" of an animal (e.g.,
antebrachiocarpal injection). The
joint may be flexed, and the needle may then be injected into the dorsal
aspect of the joint just
medial or lateral to the rnidsagittal plane. As shown in the example in Figure
2b, the
composition may be injected into the "elbow" of an animal. The joint may be in
partial flexion,
and the needle may penetrate the skin lateral and caudal to the anconeal
process and the medial
surface of the lateral humeral condyle. The example in Figure 2c shows
possible injection into
the "shoulder" of an animal (e.g., scapulohumeral injection). The needle may
enter the joint by
passing proximal to the lateral aspect of the greater tubercle of the humerus,
lateral to the
supraglenoid tubercle of the scapula, and ventral to the acromion process of
the scapula. Figure
2d shows possible injection into the "knee" or stifle joint. The joint may be
flexed sufficiently to
23
CA 02820562 2013-07-10
cause tensing of the joint capsule. The needle may enter the joint either just
medial or just lateral
to the patellar ligament midway between the distal end of the patella and
proximal articular
surface of the tibia. Passing obliquely and caudally, the needle may be
directed toward the
intercondylar space of the distal femur. However, the needle may also be
passed directly
through the patellar ligament.
[0067] The example in Figure 2e shows possible injection into the "ankle"
joint of an
animal (e.g., talocrural injection with caudal approach). The needle may enter
the joint from its
plantar-lateral aspect and is advanced in a dorsomedial and distal direction
passing between the
distal fibula and fibular tarsal bone, and joint flexion may facilitate entry
into the joint.
According to another example shown in Figure 2f, the cells may be injected
into the "hip" joint
of an animal (e.g., coxofemoral injection). According to a first ventral
approach as shown in the
left panel, the needle may enter the ventral aspect of the joint just caudal
to the body of the
pectineus muscle. Directed at a 450 angle cranially and dorsally, the needle
may pass lateral to
the ventral acetabular rim and medial to the femoral head. According to a
second lateral
approach as shown in the right panel of Figure 2f, the femur may be abducted
slightly and
rotated outward tensing the joint capsule, and the needle may pass just caudal
and medial to the
greater trochanter from a caudal to a cranial direction at an angle of
approximately 450.
Intravenous
[0068] According to embodiments of the present invention, a composition
comprising
SVF and/or AD-MSCs prepared according to methods described herein may be
administered or
injected by other more systemic means, such as by intravenous (iv,) or intra-
peritoneal (i.p.)
injection. This may be done alone or in combination with administration of the
composition to
one or more locations or joints. Intravenously injected AD-MSCs have been
shown to localize to
damaged tissues, which may be mediated by chemotactic stress signals, such as
stromal cell-
derived factor 1 (SDF-1), hepatocyte growth factor (HOF), fractallcine and
platelets. When
injected intravenously, the composition may be administered or injected in
combination with one
or more physiologically or pharmaceutically suitable carriers or solutions.
According to one
embodiment, the composition may be combined with about 6-10 ml of warmed
normal saline for
intravenous administration, which may be administered over a period of time,
such as about 20
24
CA 02820562 2013-07-10
minutes. In addition, the composition may be filtered before administration to
remove large
particles and debris prior to intravenous administration.
Adipose Stem Cell Preparation Kit
[0069) As best illustrated in Figure 3, a kit 10 is provided for preparing
a stem cell
preparation of adipose tissue from a donor or source animal. The kit 10
comprises a box or
container 12 including vessels 14 holding various solutions or preparations
used in the method,
needles 16, a cryovial 17, various pipettes 18, a sterile specimen container
19, various tubes 20,
an IV set 21, filtering units 22, mixing cannulas 23, a vile of enzyme
preparation 24 and
instructions or directions 26 for completing the method described above. In
one useful
embodiment the kit includes the following.
1. Kit A
- Solution A (e.g. PBS) ¨ 50 ml
- Vial B ¨ Medistem enzyme preparation
- Solution D (e.g. PBS + Gentacin) ¨ 19.5 ml
- Solution E - Medivet cell extraction media 5.5 ml
- Solution F (e.g. PBS + Gentacin) ¨95 ml
- Solution G ¨ ActiCell Activator Solution 2.5 ml (e.g. calcium chloride
solution)
-2 x 50m1 Polypropylene Conical Sterile Tube
- I x Mixing Cannula
- 1 x Steriflip 100um Unit
- 1 x Steriflip 60um Unit
- 2 x 8,0m1 General Purpose Large Bulb Transfer Pipette
- 2 x 15m1 Polypropylene Conical Tube
- I x 2m1 Free Standing Cryotube
- 3 x 6m1 ACD Solution A Tubes
CA 02820562 2013-07-10
- 5 x Graduated 3m1 Large Bulb Transfer Pipette
- 1 x Medivet stem cell IV blood transfusion set
- 1 x 70m1 Polystyrene Sterile Container
- Instructions
[0070] In another useful embodiment the kit includes the following.
II. Kit B
- Solution A (e.g. PBS) ¨95 ml
- Vial B ¨ Medistem enzyme preparation
- Solution D (e.g. PBS + Gentacin) ¨ 19.5 ml
- Solution E ¨ 2 x Medivet cell extraction media 5.5 ml
- Solution F (e.g. PBS 4- Gentacin) ¨95 ml
- Solution G ¨ ActiCell Activator Solution 2.5 ml (e.g. calcium chloride
solution)
-4 x 50m1 Polypropylene Conical Sterile Tube
-2 Mixing Cannula
- 2 Steriflip 10Ourn Unit
- 1 Steritlip 60um Unit
- 5 x 80m! General Purpose Large Bulb Transfer Pipette
- 1 x 15ml Polypropylene Conical Tube
- 1 x 5m1 Free Standing Cryogenic vial
-4 x 8.5m1 ACD Solution A Tubes
-3 x Graduated 3m! Transfer Pipette
- 1 x Medivet stem cell IV blood transfusion set
- 1 x 70m1 Polystyrene Sterile Container
- 3 x Spinal needle
- Instructions
26
CA 02820562 2013-07-10
[0071] The following example generally describes the preparation of the
enzyme
preparation provided in the kit and used in the method.
Example 1
[0072] The enzyme preparation product is manufactured in four discrete set
of operations
listed below.
A. Collagenase Fermentation
B. Collagenase Purification
C. Thermolysinrm Purification
D. Blending of Enzyme Preparation
A. Fermentation
[0073] Clostridium histolyticum (C. histolyticum) collagenases are
obtained from C.
histolyticum culture supernatants. These cells are obligate anaerobes and
metabolize amino
acids as an energy source.
[0074] During a production run a sample of cells are grown and expanded in
a media
formulated for cell growth until a sufficient cell volume is obtained to
inoculate the production
fennentor. A defined feed strategy is used for cell growth and enzyme
synthesis. At the end of
the fermentation the cells and cellular debris are removed from the spent
media by passage
through a 0.1 micron filter, The clarified supernatant contains the
collagenase enzymes
(Collagenase I (CI) and Collagenase II (CII)), along with at least two other
proteases, unused
fermentation media, as well as other secreted proteins and released soluble
cell lysis products.
After clarification the spent media is concentrated and diafiltered to remove
the bulk of the
remaining media and other low molecular weight components. When completed the
concentrated supernatant is frozen for further processing.
B. Collagenase Purification
[0075] The concentrated crude collagenase preparation is purified using
chromatographic
processes as has been described previously in the literature (Dwulet, FE, et
al. US Patent #
5,989,888, 1999; Kurftirst M. US Patent 7,083,964 B2, 2006; Hoelke W, et al US
Patent
application US2011/0070622 Al, 2011). All chromatographic resins and the
buffer agents used
27
CA 02820562 2013-07-10
are chemically synthetic. The final products are purified CI and CII. These
enzymes axe
characterized for their enzymatic activities and physical attributes. The
final enzyme
preparations are concentrated and stored as frozen liquids for further
blending.
C. ThermolysinTm Purification
[0076] Bacillus thermoproteolyticus Neutral Protease (ThermolysinTm) is a
commercially
available product from a manufacturer in Japan (cells are stored at the ATCC
cell bank). The
material is a partially purified preparation with lot to lot variability in
specific activity and
contamination profile. This material is further purified using a combined
solubilization and ion
exchange process to reduces the contaminate levels so that each preparation
has, within the
experimental error of the assay, the same lot to lot specific activity. The
enzyme can be stored in
bulk as a frozen liquid.
D. Blending of Enzyme Preparation
[0077] The blend of enzymes for the final enzyme preparation is composed
of
Collagenase I, Collagenase II and ThermolysinTm blended in appropriate ratios
to maximize the
recovery of functional cells from animal adipose tissue (about 60 wt%
collagenase and 40 wt%
protease). The blended enzymes are then frozen and lyophilized. They may be
subsequently
mixed with a biologically inert protein stabilizer to make the final enzyme
preparation for use in
the disclosed method (e.g. 20-30 wt% enzyme mixture and 70-80 wt% biologically
inert protein
stabilizer).
[0078] The foregoing has been presented for purposes of illustration and
description. It
is not intended to be exhaustive or to limit the embodiments to the precise
form disclosed.
Obvious modifications and variations are possible in light of the above
teachings. All such
modifications and variations are within the scope of the appended claims when
interpreted in
accordance with the breadth to which they are fairly, legally and equitably
entitled.
28
